Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | DHODH | Q02127 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6068453 | 0.87 | PDE5A (0.68) | PDE5AMAPTKDM4EALDH1A1DHODH | |
| SCHEMBL6068237 | 0.81 | PDE5A (0.77) | PDE5AMAPTKDM4EALDH1A1DHODH | |
| SCHEMBL290735 | 0.80 | PDE5A (0.78) | PDE5AMAPTKDM4EALDH1A1DHODH | |
| SCHEMBL6068285 | 0.79 | MAPT (0.72) | PDE5AMAPTKDM4EALDH1A1DHODH | |
| SCHEMBL290868 | 0.79 | PDE5A (0.65) | PDE5AMAPTKDM4EALDH1A1DHODH | |
| SCHEMBL28862568 | 0.78 | PDE5A (0.66) | PDE5AMAPTKDM4EALDH1A1DHODH | |
| SCHEMBL291120 | 0.77 | PDE5A (0.76) | PDE5AMAPTKDM4EALDH1A1DHODH | |
| SCHEMBL290844 | 0.76 | PDE5A (1.00) | PDE5AMAPTKDM4EALDH1A1DHODH | |
| SCHEMBL5862466 | 0.76 | PDE5A (0.44) | PDE5AMAPTKDM4EALDH1A1DHODH | |
| SCHEMBL28581338 | 0.76 | PDE5A (0.74) | PDE5AMAPTKDM4EALDH1A1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087614-B2 | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 | BRISTOL-MYERS SQUIBB CO. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20030162802-A1 | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162802-A1 | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 | PDE7A, PDE7B, PDE3A | PDE5A 5/4885MAPT 4514/4885KDM4E 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.